Recent advances in theranostics and oncology PET: emerging radionuclides and targets

Watabe, Tadashi; Hirata, Kenji; Iima, Mami et al.

Annals of Nuclear Medicine, 2025, 39(9), 909-921

Number of Access:40（2025-11-03 03:06 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/102738

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
AnnNuclMed_39_9_909 pdf None 1.26 MB 33 2025.09.19  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Recent advances in theranostics and oncology PET: emerging radionuclides and targets
Creator
NRID
1000090648932 1000090648932
ORCID
0000-0001-8658-2395 0000-0001-8658-2395
researchmap permalink
twosaka2018 twosaka2018
Scopus Author ID
57421862900 57421862900
CreatorName
Watabe, Tadashi
NRID
1000030431365 1000030431365
CreatorName
Hirata, Kenji
NRID
1000060748797 1000060748797
CreatorName
Iima, Mami
NRID
1000000546872 1000000546872
ORCID
0000-0002-0911-6769 0000-0002-0911-6769
researchmap permalink
myMY3434 myMY3434
Scopus Author ID
36891136200 36891136200
CreatorName
Yanagawa, Masahiro
NRID
1000080719485 1000080719485
CreatorName
Saida, Tsukasa
NRID
1000010838981 1000010838981
CreatorName
Sakata, Akihiko
NRID
1000090565657 1000090565657
CreatorName
Ide, Satoru
NRID
1000040957057 1000040957057
CreatorName
Honda, Maya
NRID
1000070878511 1000070878511
CreatorName
Kurokawa, Ryo
NRID
1000080463743 1000080463743
CreatorName
Nishioka, Kentaro
NRID
1000080732685 1000080732685
CreatorName
Kawamura, Mariko
NRID
1000080813336 1000080813336
CreatorName
Ito, Rintaro
NRID
1000050535820 1000050535820
CreatorName
Takumi, Koji
CreatorName
Oda, Seitaro
CreatorName
Sugawara, Shunsuke
NRID
1000090622027 1000090622027
CreatorName
Sofue, Keitaro
NRID
1000090779480 1000090779480
CreatorName
Ueda, Daiju
NRID
1000050242863 1000050242863
CreatorName
Naganawa, Shinji
Subject
Astatine
Positron emission tomography
PSMA
Radioligand therapy
SSTR
Terbium
Theranostics
Description
The version of record of this article, first published in Annals of Nuclear Medicine 39 (2025), is available online at Publisher’s website: https://doi.org/10.1007/s12149-025-02090-z.
Abstract
Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (¹⁶¹Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to ¹⁷⁷Lu. Alpha emitters, such as astatine (²¹¹At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [²¹¹At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.
Publisher
Springer
Source Title
Annals of Nuclear Medicine
Volume (Issue)
39(9)
Page
909-921
Date of Issued
2025-07-27
Language
English
Handle URL
https://hdl.handle.net/11094/102738
PISSN
09147187
eISSN
18646433
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1007/s12149-025-02090-z
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article